NCT02232646撤回2 期
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Disease Control Rate (DCR)
研究概览
简要总结
This is an open label, multi-center, Phase II study of BBI503 administered to adult patients with selected advanced urologic malignancies. The primary objective of this study is to evaluate the disease control rate of patients with renal cell cancer and urothelial carcinoma treated with BBI503.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Histologically or cytologically confirmed renal cell cancer or urothelial carcinoma that is metastatic, unresectable, or recurrent.
- •≥ 18 years of age
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI503 dose
- •Females of childbearing potential must have a negative serum pregnancy test
- •Alanine transaminase (ALT) ≤ 2.5 x the upper limit of normal (ULN), or ≤ 3.5 x ULN in the presence of primary or metastatic hepatic lesions
- •Hemoglobin (Hgb) ≥ 10 g/dl
- •Total bilirubin ≤ 1.5 x ULN
- •Creatinine ≤ 1.5 x ULN or creatinine clearance > 50 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
- •Absolute neutrophil count ≥ 1.5 x 10^9/L
- •Platelets ≥ 100 x 10^9/L
- •Prothrombin time (PT) ≤ 16 seconds and partial thromboplastin time (PTT) ≤ 1.5 x ULN
- •Life expectancy ≥ 3 months
- •A patient with renal cell carcinoma (RCC) must be classified into clear-cell or non-clear cell subtype, and must then meet the following criteria:
- •Patients with clear cell renal cancer must have received prior treatment with at least one line of standard systemic therapy which included treatment with a tyrosine kinase inhibitor; either alone or in combination. The patient must have had either progressive disease during treatment, or have had documented intolerance to first line tyrosine kinase inhibitor (TKI)-based therapy.
- •Patients with clear cell renal cancer who have received anti-cancer treatment beyond first-line TKI-based therapy may enroll.
- •Patients with clear cell renal cancer who have not received anti-cancer treatment beyond first-line TKI-based therapy may enroll only after discussing the potential risks and benefits of alternative treatment options, such as other currently available agents approved for treatment of patients with clear cell renal cancer.
- •Patients with non-clear cell RCC which is metastatic may enroll without having received prior treatment in the metastatic setting
- •A patient with urothelial carcinoma must also meet the following criteria:
- •Must have received at least one prior line of standard systemic cytotoxic therapy in the metastatic setting.
排除标准
- •Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of first dose of BBI
- •Patients may begin BBI503 on a date determined by the investigator and medical monitor for the sponsor provided there is a minimum of 7 days since last receiving anti-cancer treatment, and that all prior treatment-related adverse events (AEs) have resolved or have been deemed irreversible.
- •Major surgery within 4 weeks prior to first dose (requiring general anesthesia and/or inpatient hospitalization for recovery).
- •Any known symptomatic or untreated brain metastases requiring increase of steroid dose within 2 weeks prior to starting on study. Patients with treated brain metastases must be stable for 4 weeks after completion of that treatment. Post-treatment image documentation of stability is required within 4 months of starting on study. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated.
- •Pregnant or breastfeeding
- •Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)
- •Unable or unwilling to swallow BBI503 capsules daily
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements (e.g. no reliable transportation).
- •Patients with a history of malignancies other than the tumor of interest except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 3 years.
- •Abnormal ECGs which are clinically significant such as QT prolongation - QTc > 480 msec, clinically significant cardiac enlargement or hypertrophy, new bundle branch block, or signs of active ischemia. Patients with evidence of prior infarction who are New York Heart Association (NYHA) functional class II, III, or IV are excluded, as are patients with marked arrhythmia such as Wolff Parkinson White pattern or complete atrioventricular (AV) dissociation.
研究组 & 干预措施
BBI503
Experimental
干预措施: BBI503 (Drug)
结局指标
主要结局
Disease Control Rate (DCR)
时间窗: 8 weeks
Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.
次要结局
- Objective Response Rate (ORR)(8 weeks)
- Progression Free Survival (PFS)(24 months)
- Number of Patients with Adverse Events(24 months)
- Overall Survival (OS)(24 months)
- Pharmacodynamics (biomarkers) of BBI503 when tumor biopsy is possible(baseline, 4 weeks)
研究者
相似试验
已完成
2 期
A Study of BBI503 in Adult Patients With Advanced Hepatobiliary CancerHepatocellular CarcinomaCholangiocarcinomaNCT02232633Sumitomo Pharma America, Inc.45
终止
2 期
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal TumorsGastrointestinal Stromal TumorsNCT02232620Sumitomo Pharma America, Inc.2
已完成
1 期
A Study of BBI503 in Adult Patients With Advanced Solid TumorsCancer, Advanced Solid TumorsNCT01781455Sumitomo Pharma America, Inc.311
已完成
1 期
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced CancerCancerNCT02483247Sumitomo Pharma America, Inc.165
已完成
1 期
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid TumorsAdvanced Solid TumorsCancerNCT02432326Sumitomo Pharma America, Inc.147